Pneumatosis intestinalis (PI) is a rare complication of chemotherapy, characterized by multiple gas accumulations within the bowel wall.
Case presentation
A 71-year-old woman with epidermal growth factor receptor (EGFR) mutation-positive lung adenocarcinoma was admitted to our hospital because of reduced consciousness. She was diagnosed as having leptomeningeal carcinomatosis (LM) using lumbar puncture. Because she could not swallow a tablet, erlotinib was administered via a feeding tube. Her state of consciousness gradually improved, but she experienced diarrhea several times a day. After 3 weeks of erlotinib therapy, PI occurred. Erlotinib was discontinued and PI was resolved after treatment with conservative therapies. Erlotinib was re-administrated and PI occurred again. After improvement of erlotinib-induced PI, gefitinib was administered by a feeding tube and the patient did not experience PI or diarrhea. The patient survived 8 months from the diagnosis of LM.
Conclusion
PI is one of the side effects of erlotinib, and consecutive therapies are useful for the treatment of PI. In this patient, gefitinib was successfully administered after erlotinib-induced PI.
Pneumatosis intestinalis (PI) is a rare complication of chemotherapy including cytotoxic and molecular-targeted agents [1], and is characterized by multiple gas accumulations within the bowel wall. PI mainly occurs when gas enters the submucosal and subserosal tissue of the bowel wall with infiltration of giant cells [2]. The gas is thought to come from the intraluminal gastrointestinal system, bacterial production, or a pulmonary source [3]. Besides chemotherapy, PI is associated with various medical conditions, such as collagen-vascular diseases, lupus enteritis, infectious colitis, asthma, acquired immune deficiency syndrome, cystic fibrosis, hematopoietic stem cell transplantation, trauma, and steroid therapy [2‐4]. Compared with cytotoxic agents, PI due to molecular-targeted agents is even rarer [1, 5‐12], and only several cases have been reported in association with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) [1, 13‐17]. Here, we describe a patient with leptomeningeal carcinomatosis (LM) caused by EGFR-mutated lung adenocarcinoma who was treated with gefitinib via a feeding tube after erlotinib-induced PI.
Case presentation
A 71-year-old Japanese woman was admitted to Toranomon hospital because of reduced consciousness. She had a history of a mastectomy for right breast cancer. Eight months before admission, she came to our hospital because of partial paralysis of her right hand. A chest computed tomography (CT) scan showed a mass in the left upper lobe, as well as mediastinal and left hilar lymphadenopathy. Brain magnetic resonance imaging (MRI) showed multiple brain metastases. The patient was diagnosed with EGFR mutation-positive adenocarcinoma using transbronchial lung biopsy. She received 4 cycles of carboplatin and paclitaxel chemotherapy, and gamma knife treatment followed by whole brain radiation for brain metastases. Although chemotherapy resulted in a partial response, her state of consciousness rapidly worsened in the 2 weeks before admission. Her level of consciousness on admission was a Glasgow Come Scale (GCS) score of 8. She could not speak or move her extremities. A lumbar puncture was performed and cytological examination of her cerebrospinal fluid revealed adenocarcinoma cells. EGFR mutation analysis of cerebrospinal fluid was positive for L858R, but negative for exon 20 T790 M. Erlotinib at 150 mg/day was dissolved in 15 mL of water, and was administered via a feeding tube because she could not swallow a tablet. At the same time, 8 mg/day dexamethasone and glycerin administration were started via drip infusion. The patient’s state of consciousness gradually improved to a GCS score of 13, and serum levels of CA19–9 decreased from 3031 U/mL to 292 U/mL. As a side effect of erlotinib, diarrhea of the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade 2 developed. Three weeks after receiving erlotinib and steroids, the patient started to vomit and suffered from grade 3 diarrhea. At that time, her body temperature, blood pressure, and pulse rate were 36.8 °C, 105/55 mmHg and 92 b.p.m., respectively. There was no abdominal tenderness on her physical examinations. The laboratory test results showed a normal leukocyte count (4700/mL), and a slightly increased C-reactive protein level (2.4 mg/dL). Arterial blood gas analysis showed alkalemia (pH 7.50). An abdominal radiograph showed a dilated colon and the presence of intraluminal air along the wall of the colon (Fig. 1). A CT scan of the abdomen demonstrated pneumatosis; there was a thickening of the colon with free air, pneumoretroperitoneum, and pneumomediastinum (Fig. 2). There were no signs of bowel ischemia or portal venous air. Erlotinib and steroids were stopped, and the patient was managed conservatively with a combination of antibiotics and inhalation of oxygen. Two weeks later, the CT findings of PI were improved. Erlotinib was re-administered without steroids, and PI relapsed 4 weeks later with diarrhea. After improving PI by discontinuation of erlotinib and conservative therapies, gefitinib was administered safely without PI and diarrhea for 3 month. At that time, the EGFR-TKIs afatinib and osimertinib were available in the Japanese market. The number of cells in the cerebral fluid decreased from 132/μL to 37/μL with erlotinib and gefitinib, although the cytology was still positive for adenocarcinoma. The patient died of worsening brain metastases 8 months after the diagnosis of LM.
Fig. 1
An abdominal radiograph showed a dilated colon and the presence of intraluminal air along the wall of the colon with free air (arrow)
Fig. 2
A CT scan of the abdomen demonstrated a thickening of the colon with free air, pneumoretroperitoneum, and pneumomediastinum
×
×
Anzeige
Discussion
We describe a patient with LM from EGFR-mutated lung adenocarcinoma who was treated with erlotinib followed by gefitinib through a feeding tube for 8 months. As adverse events of erlotinib, PI and grade 3 diarrhea developed, both of which were resolved after treatment with conservative therapies. Subsequently, gefitinib could be administered without either PI or diarrhea.
The precise mechanism by which gefitinib was administered safely instead of erlotinib in this patient is unclear. In comparison of side effects between erlotinib and gefitinib, hepatotoxicity was more common in gefitinib, but rash was more common in erlotinib; the incidence of diarrhea and interstitial lung disease was almost the same [18]. However, there have been several reports of successful treatments with erlotinib after gefitinib-induced interstitial lung disease [19‐22]. One of these reports suggested the hypothesis that minor differences in the chemical structure between two drugs binding to the common quinazoline and anilino rings might influence the results [20].
PI can be caused by various agents, such as cyclophosphamide, methotrexate, vincristine, doxorubicin, daunorubicin, cytarabine, fluorouracil, paclitaxel, docetaxel, etoposide, irinotecan, 5 fluorouracil (5-FU), and cisplatin [12, 14]. PI secondary to molecular-targeted agents is very rare [1, 5‐14]. Most patients received molecular-targeted therapy alone, and were treated conservatively for PI [1]. Regarding EGFR-TKIs, PI was reported following gefitinib and erlotinib treatment in several case reports [1, 13‐17] (Table 1). These patients presented with gastrointestinal symptoms, such as diarrhea or constipation, and PI was improved by conservative therapies and discontinuation of TKIs.
Table 1
Previous case reports of pneumatosis intestinalis following gefitinib and erlotinib treatment
Year
Author
Age
Sex
EGFR-TKIs
CT findings
Treatment
2012
Shinagare, et al. 1)
N.D.
N.D.
Erlotinib
N.D.
N.D.
2012
Iwasaku, et al. 13)
82
F
Gefitinib
Intramural air within the intestinal wall
Conservative therapy
2012
Lee, et al. 14)
66
F
Gefitinib
Intramural air within the intestinal wall, portal venous air, Infarction of liver
Conservative therapy
2014
Hughes, et al. 15)
N.D. Three patients
N.D.
Erlotinib and pertuzumab
N.D.
N.D.
2015
Ando, et al. 16)
71
M
Gefitinib
Intramural air within the intestinal wall, ascites
Conservative therapy
2016
Maeda, et al. 17)
80
F
Gefitinib
Intramural air within the intestinal wall, pneumoretroperitoneum,
Conservative therapy
2017
Current case
71
F
Erlotinib
Intramural air within the intestinal wall, pneumoretroperitoneum, pneumomediastinum
The precise mechanism of PI secondary to EGFR-TKIs is unknown. EGFR-TKIs have gastrointestinal toxicities, such as diarrhea, nausea, and vomiting. Gastrointestinal toxicities and the subsequent loss of mucosal integrity of the bowel wall may contribute to PI secondary to EGFR-TKIs. In the present case, we were able to treat the patient with gefitinib and erlotinib-induced PI because she did not experience diarrhea after the switch to gefitinib.
Anzeige
The radiological findings of PI were first reported on abdominal radiograph, and the features were submucosal and subserosal cysts formed in ellipses/circles within the bowel wall [23]. However, nowadays, CT is more useful for the diagnosis of PI [3, 24]. Typical CT findings are submucosal and subserosal air within the bowel wall and free air [25, 26]. Like in our patient, PI is sometimes accompanied by pneumomediastinum, which occurs when retroperitoneal and peritoneal air enters along the para-aortic tissues and exits thorough the esophageal hiatus into the mediastinum [27, 28].
Conclusions
PI is one of the side effects of EGFR TKIs, and is usually treated with conservative therapies. In this patient, gefitinib was successfully administered after erlotinib-induced PI.
Availability of data and materials
Data are available on request due to privacy.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Written informed consent for publication of this case report and associated images could not be obtained from the patient because of reduced consciousness, but the patient’s husband provided written informed consent for the publication of the case report and accompanying images.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Unter modernen Systemtherapien versechsfacht sich das VTE-Risiko. Warum diese Daten relevant für die Behandlung krebsassoziierter Thrombosen sind, erläutert Prof. F. Langer im Interview. So kann es durch Immuntherapien zu inflammatorischen Syndromen z.B. im GI-Trakt kommen. Nebenwirkungen wie Durchfall oder Mukositis haben dann Einfluss auf die Wirksamkeit oraler Antikoagulantien. Aber auch in punkto Blutungsrisiko ist Vorsicht geboten. Wann hier bevorzugt NMH eingesetzt werden sollten, erläutert Prof. Langer im Interview.
Krebsassoziierte venöse Thromboembolien (CAT) haben in den vergangenen Jahren stetig zugenommen. Was hat der Anstieg mit modernen Antitumortherapien zu tun? Venöse Thromboembolien sind relevante Morbiditäts- und Mortalitätsfaktoren in der Onkologie. Besonders hoch sind die Risiken bei Tumoren des Abdominalraums. Eine antithrombotische Primärprophylaxe ist daher gerade bei gastrointestinalen (GI-) Tumoren auch im ambulanten Setting wichtig.
Die Thromboembolie ist neben Infektionen die zweithäufigste Todesursache bei Krebspatienten. Die Behandlung der CAT (cancer associated thrombosis) ist komplex und orientiert sich am individuellen Patienten. Angesichts einer Vielzahl zur Verfügung stehender medikamentöser Behandlungsoptionen finden Sie hier Video-Experteninterviews, Sonderpublikationen und aktuelle Behandlungsalgorithmen zur Therapieentscheidung auf Basis von Expertenempfehlungen.
Mit dem Update der Clinical Practice Guidelines 2023 zum metastasierenden nicht-kleinzelligen Lungenkarzinom (mNSCLC) trägt die ESMO der in den letzten Jahren immer weiter gewachsenen Anzahl an Therapieoptionen Rechnung.
Mit NOVUM Onkologie veranstaltet MSD regelmäßig Online-Fortbildungen zum Thema Lungenkarzinom. Bei dem mittlerweile etablierten Format erhalten Teilnehmende die Möglichkeit sich bei Expertendiskussionen zu praxisrelevanten Themen der pneumologischen Onkologie weiterzubilden.
Die Einführung von Immun-Checkpoint-Inhibitoren markierte einen entscheidenden Fortschritt in der Behandlung von bestimmten Patienten mit nicht-kleinzelligem Lungenkarzinom (non-small cell lung cancer, NSCLC) und eröffnete seither neue Perspektiven und Chancen für Behandler und geeignete Patienten. Hier finden Sie fortlaufend aktuelle Informationen und relevante Beiträge zur Immunonkologie in dieser Indikation.
In der topischen Prävention der akuten Radiodermatitis werden Zubereitungen mit Dexpanthenol oder Harnstoff von deutschsprachigen Fachkreisen in der Radioonkologie am häufigsten empfohlen und als am wirksamsten bewertet. Bei der Behandlung der strahlenbedingten Hautschäden liegen Topika mit Dexpanthenol oder Kortikosteroide vorn [1].
Einer klinischen Studie zufolge wendet nur etwa die Hälfte der Ekzem-Patient:innen ihre topische Therapie mit Kortikosteroiden wie verordnet an. Darüber hinaus nahm die Adhärenz im Zeitverlauf weiter ab. Bei einer gleichzeitig applizierten barrierestabilisierenden Basiscreme blieb die Anwendungsfrequenz dagegen über die Zeit stabil [1].
Bepanthen® Wund- und Heilsalbe wird heute wie bei der Einführung vor 70 Jahren erfolgreich bei kleinen Alltagsverletzungen eingesetzt. Moderne Forschung – Untersuchungen an Hautmodellen, Genexpressionsanalysen und klinische Studien – schafft darüber hinaus Evidenz für neue Anwendungsgebiete. So kann die Dexpanthenol-haltige Salbe heute z.B. zur Nachbehandlung einer Lasertherapie bei aktinischer Keratose oder Tattoo-Entfernung eingesetzt werden. Erfahren Sie hier mehr über moderne Forschung zu Bepanthen.
